Algorics Analytics Solution acuity Selected by US CRO Lexitas to Drive Optimized Clinical Operations Services
Houston, TX, USA, For Release: 8th September 2015. Algorics, a provider of clinical analytics solutions and software for the global life sciences industry, today announced that acuity, its analytics solution for risk based monitoring, has been adopted by Lexitas Pharma Services, Inc. The US Ophthalmology-focused CRO will leverage the acuity solution to bring together internal and external data sources in order to provide analytics dashboards and alerts to give the leadership team a real-time picture of key operational parameters and KRI (key risk indicators) and allow operational teams to more easily manage trial performance.
“As Lexitas grows we continue to look for innovative ways to improve efficiency without compromising the high quality and tailored services our clients count on. Implementing acuity will provide us with a timely and comprehensive view of how our portfolio of trials is performing, as well as enable us to manage individual trials in the most effective way,” said Chad Ice, President, Lexitas.
Nick Hargaden, President, Algorics said, “We are delighted that Lexitas has chosen acuity to provide centralized insights into the clinical trials they manage, thus driving operational effectiveness and resource savings.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Full Phase IIIb BATURA Trial Results Show Airsupra Cuts Severe Exacerbations by 47% in Mild Asthma
May 20th 2025Results from the pivotal BATURA trial show that Airsupra (albuterol/budesonide) significantly outperformed albuterol monotherapy in reducing severe asthma exacerbations and systemic corticosteroid exposure, reinforcing its role as a next-generation, anti-inflammatory rescue therapy for mild asthma patients.
